InterCure (NASDAQ:INCR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
InterCure (NASDAQ:INCR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation
InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow [Yahoo! Finance]
InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow